BLADDER CANCER
Clinical trials for BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new BLADDER CANCER trials appear
Sign up with your email to follow new studies for BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control TerminatedThis study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …
Matched conditions: BLADDER CANCER
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Matched conditions: BLADDER CANCER
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Pfizer tests new drug combo for advanced cancers – but study ends early
Disease control TerminatedThis early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…
Matched conditions: BLADDER CANCER
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Matched conditions: BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental cancer drug LY3405105 fails to advance in early trial
Disease control TerminatedThis early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…
Matched conditions: BLADDER CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise for tough bladder cancer
Disease control TerminatedThis study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …
Matched conditions: BLADDER CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Matched conditions: BLADDER CANCER
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Bladder cancer trial halted: could trilaciclib have saved bone marrow?
Disease control TerminatedThis phase 2 trial tested whether adding trilaciclib (Cosela) to standard chemotherapy and avelumab could help people with advanced bladder cancer by protecting their bone marrow. The study enrolled 92 adults with untreated, locally advanced or metastatic urothelial carcinoma. Un…
Matched conditions: BLADDER CANCER
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
New urine test aims to catch bladder cancer early
Diagnosis TerminatedThis study tested a urine test that measures a protein called DEK to help diagnose bladder cancer. It included over 1,100 people with blood in their urine or painful urination. The goal was to see if the test could accurately detect cancer without invasive procedures. However, th…
Matched conditions: BLADDER CANCER
Sponsor: Medical Diagnostic Laboratories, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Can retelling and deep breathing ease trauma in terminal cancer?
Symptom relief TerminatedThis Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…
Matched conditions: BLADDER CANCER
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Bladder cancer drug adstiladrin studied in everyday practice
Knowledge-focused TerminatedThis study followed 202 bladder cancer patients who were prescribed Adstiladrin (nadofaragene firadenovec) in real-world clinics in the US and Israel. Researchers wanted to see how often the drug led to complete remission and how long that lasted. The study was terminated early, …
Matched conditions: BLADDER CANCER
Sponsor: Ferring Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Can a simple urine test replace tumor biopsies for bladder cancer treatment?
Knowledge-focused TerminatedThis study looked at whether genetic changes found in urine could match those in tumor tissue for people with high-risk non-muscle invasive bladder cancer. The goal was to see if a urine test could help doctors choose the best immunotherapy for each patient. The study planned to …
Matched conditions: BLADDER CANCER
Sponsor: Hopital Foch • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC